Association between class III β-tubulin expression and response to paclitaxel/vinorebine-based chemotherapy for non-small cell lung cancer: A meta-analysis

Lung Cancer

Volumn 77, Issue 1, 2012, Pages 9-15

  Zhang, Hai Long ^a   Ruan, Li ^a   Zheng, Li Mou ^a,b   Whyte, David ^a   Tzeng, Chi Meng ^a,b   Zhou, Xi Wu ^a  

^a Amoy Diagnostics Co LTD   (China)

^b XIAMEN UNIVERSITY   (China)

Author keywords

Chemotherapy; Class III tubulin; Meta analysis; Non small cell lung cancer; Paclitaxel; TUBB3; Vinorebine

Indexed keywords

BETA TUBULIN; CLASS III BETA TUBULIN; NAVELBINE; PACLITAXEL; UNCLASSIFIED DRUG;

ASIAN; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CAUCASIAN; EMBASE; HUMAN; LUNG NON SMALL CELL CANCER; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; GENE EXPRESSION; HUMANS; LUNG NEOPLASMS; PACLITAXEL; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUBULIN; VINBLASTINE;

EID: 84862820442     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.01.005     Document Type: Review

References (31)

1. SEER cancer statistics review, 1975-2006 2009, National Cancer Institute, Bethesda, MD, based on November 2008 SEER data submission, posted to the SEER website, 2009. http://seer.cancer.gov/csr/1975%202006/, M.J. Horner, L.A.G. Ries, M. Krapcho, N. Neyman, R. Aminou, N. Howlader (Eds.).
2. Rasco D.W., Yan J., Xie J., Yang X., Dowell J.E., Gerber D.E. Looking beyond surveillance, epidemiology, and end results: patterns of chemotherapy administration for advanced non-small cell lung cancer in a contemporary, diverse population. J Thorac Oncol 2010, 5:1529-1535.
3. Depierre A., Chastang C.I., Quoix E., Lebeau B., Blachon F., Paillot N., et al. Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial. Ann Oncol 1994, 5:37-42.
4. Douillard J.Y., Rosell R., De Lena M., Carpagnano F., Ramlau R., Gonzalez-Larriba J.L. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomized control led trial. Lancet Oncol 2006, 7:719-727.
5. Winton T., Livingston R., Johnson D., Rigns J., Johnston M., Butts C., et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005, 352:2589-2597.
6. Dumontet C., Isaac S., Souque P.J., Bejui-Thivolet F., Pacheco Y., Peloux N. Expression of class III β tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. Bull Cancer 2005, 92:E25-E30.
7. Burkhart C.A., Kavallaris M., Horwitz S.B. The role of β-tubulin isotypes in resistance to antimitotic drugs. Biochim Biophys Acta 2001, 1471:1-9.
8. Ozalp S.S., Yalcin O.T., Tanir M., Kabukcuoglu S., Etiz E. Multidrug resistance gene-1 (Pgp) expression in epithelial ovarian malignancies. Eur J Gynaecol Oncol 2002, 23:337-340.
9. Mesquita B., Veiga I., Pereira D., Tavares A., Pinto I.M., Pinto C., et al. No significant role for tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatin. BMC Cancer 2005, 5:101.
10. Wertz I.E., Kusam S., Lam C., Okamoto T., Sandoval W., Anderson D.J., et al. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature 2011, 471:110-114.
11. Wang J., Pu X.L., Yu M.F., Ma Z.L., Wang Z.L. The relationship between expression of class III-tubulin expression and therapeutic effect of vinorelbine on non-small cell lung cancer. Chin Clin Oncol 2008, 13:205-208.
12. Sève P., Issac S., Tredan O., Souquet P.J., Pacheco Y., Perol M., et al. Expression of class III-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res 2005, 11:5481-5486.
13. Sève P., Mackey J., Isaac S., Tredan O., Souquet P.J., Perol M., et al. Class III-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther 2005, 4:2001-2007.
14. Yang J.Q., Gao X.S., Liu H.X., Chun H. Relationship between expression of β III-tubulin and drug resistance to taxane in stage IV non-small cell lung cancer. J Fourth Mil Med Univ 2008, 10:930-932.
15. Yang J.Q., Wang H.B., Liu H.X. Relationship between expression of β III-tubulin, stathmin and drug resistance to taxane in local advanced non-small cell lung cancer. Chin Clin Oncol 2009, 10:884-889.
16. Pu X.L., Wang J., Xu L., Ma J.Q., Wang Z.L., Liu F.Y., et al. Relationship between expression of tubulin-III plus stathmin in advanced non-small cell lung cancer and its sensitivity to vinorelbine chemotherapy. Chin J Lung Cancer 2009, 01:3419-3424.
17. Rosell R., Scagliotti G., Danenberg K.D., Lord R.V., Bepler G., Novell O., et al. Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene 2003, 22:3548-3552.
18. Du Y.M., Wang B.H., Wang T.Y., Ha M.W., Wang Z.B. Change of stathmin and tubulin III expression in NSCLC and its influence to taxol sensitivity. Shandong Med J 2010, 38:18-23.
19. Azuma K., Sasada T., Kawahara A., Takamori S., Hattori S., Ikeda J., et al. Expression of ERCC1 and class III (beta)-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel. Lung Cancer 2009, 64:326-333.
20. Xiao Y.Y., Song Y., Shi Y. ERCC1 and class III beta-tubulin protein expression in relation to tumor and survival of stage IIIB/IV NSCLC patients treated with TP/NP chemotherapy regimens. Chin J Lung Cancer 2009, 01:14-16.
21. Okuda K., Sasaki H., Dumontet C., Kawano O., Yukiue H., Yokoyama T., et al. Expression of excision repair cross-complementation group 1 and class III β tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer. Lung Cancer 2008, 62:105-112.
22. Wells G.A., Shea B., O'Connell D., Peterson J., Welch V., Losos M., et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses 2003, Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm.
23. Millett G.A., Flores S.A., Marks G., Reed J.B., Herbst J.H. Circumcision status and risk of HIV and sexually transmitted infections among men who have sex with men: a meta-analysis. JAMA 2008, 300:1674-1684.
24. WHO handbook for reporting results of cancer treatment 1979, World Health Organization Offset Publication No. 48, Geneva, Switzerland.
25. Mantel N., Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959, 22:719-748.
26. Chen S.F., Zhang J., Wang R., Luo X.Y., Chen H.Q. The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1expression better than high/positive ERCC1 expression? A meta-analysis. Lung Cancer 2010, 70:63-70.
27. Schoenleber S.J., Kurtz D.M., Talwalkar J.A., Roberts L.R., Gores G.J. Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer 2009, 100:1385-1392.
28. Borenstein M., Hedges L., Rothstein H. Introduction to meta-analysis 2007, vol. 6. p. 85-115. Available at: http://www.meta-analysis.com/downloads/.
29. Urano N., Fujiwara Y., Doki Y., Kim S.J., Miyoshi Y., Noguchi S., et al. Clinical significance of class III beta-tubulin expression and its predictive value for resistance to docetaxel-based chemotherapy in gastric cancer. Int J Oncol 2006, 28:375-381.
30. Seve P., Reiman T., Lai R., Hanson J., Santos C., Johnson L., et al. Class III beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site. Cancer Chemother Pharmacol 2007, 60:27-34.
31. Hasegawa S., Miyoshi Y., Egawa C., Ishitobi M., Taguchi T., Tamaki Y., et al. Prediction of response to docetaxel by quantitative analysis of class I and III beta-tubulin isotype mRNA expression in human breast cancers. Clin Cancer Res 2003, 9:2992-2997.